[go: up one dir, main page]

SI3716992T1 - Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj - Google Patents

Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj

Info

Publication number
SI3716992T1
SI3716992T1 SI201830749T SI201830749T SI3716992T1 SI 3716992 T1 SI3716992 T1 SI 3716992T1 SI 201830749 T SI201830749 T SI 201830749T SI 201830749 T SI201830749 T SI 201830749T SI 3716992 T1 SI3716992 T1 SI 3716992T1
Authority
SI
Slovenia
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
treat angiogenic
treat
Prior art date
Application number
SI201830749T
Other languages
English (en)
Inventor
Robert L. Vitti
Alyson J. Berliner
Karen Chu
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64755724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3716992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of SI3716992T1 publication Critical patent/SI3716992T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SI201830749T 2017-11-30 2018-11-29 Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj SI3716992T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593033P 2017-11-30 2017-11-30
US201862644425P 2018-03-17 2018-03-17
US201862748782P 2018-10-22 2018-10-22
EP18825837.0A EP3716992B1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders
PCT/US2018/063025 WO2019108770A1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (1)

Publication Number Publication Date
SI3716992T1 true SI3716992T1 (sl) 2022-10-28

Family

ID=64755724

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830749T SI3716992T1 (sl) 2017-11-30 2018-11-29 Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj

Country Status (23)

Country Link
US (2) US10973879B2 (sl)
EP (3) EP4122486A1 (sl)
JP (2) JP7339248B2 (sl)
KR (2) KR20200093621A (sl)
CN (1) CN111465407A (sl)
AU (2) AU2018375398B2 (sl)
BR (1) BR112020010659A2 (sl)
CA (1) CA3083611A1 (sl)
DK (1) DK3716992T3 (sl)
ES (1) ES2927049T3 (sl)
HR (1) HRP20221335T1 (sl)
HU (1) HUE059827T2 (sl)
IL (2) IL312323A (sl)
LT (1) LT3716992T (sl)
MX (1) MX2020005166A (sl)
PL (1) PL3716992T3 (sl)
PT (1) PT3716992T (sl)
RS (1) RS63703B1 (sl)
SG (1) SG11202004268PA (sl)
SI (1) SI3716992T1 (sl)
SM (1) SMT202200374T1 (sl)
WO (1) WO2019108770A1 (sl)
ZA (1) ZA202002821B (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
IL295808B2 (en) 2015-12-03 2023-10-01 Regeneron Pharma Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
IL308505A (en) * 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
US20230295266A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100659477B1 (ko) 1999-06-08 2006-12-20 리제네론 파라마큐티칼스 인코포레이티드 개선된 약물동태학적 성질을 가지는 변형된 키메라 폴리펩티드
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
AU2016358111B2 (en) * 2015-11-18 2021-11-18 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂

Also Published As

Publication number Publication date
AU2018375398A1 (en) 2020-06-18
CN111465407A (zh) 2020-07-28
EP3716992B1 (en) 2022-08-10
AU2025201179A1 (en) 2025-03-13
LT3716992T (lt) 2022-09-12
BR112020010659A2 (pt) 2020-11-10
ES2927049T3 (es) 2022-11-02
IL274711A (en) 2020-07-30
AU2018375398B2 (en) 2024-11-21
US10973879B2 (en) 2021-04-13
SMT202200374T1 (it) 2022-11-18
JP7339248B2 (ja) 2023-09-05
JP2023159323A (ja) 2023-10-31
PL3716992T3 (pl) 2022-12-19
DK3716992T3 (da) 2022-09-12
HRP20221335T1 (hr) 2022-12-23
WO2019108770A1 (en) 2019-06-06
PT3716992T (pt) 2022-08-31
EP3716992A1 (en) 2020-10-07
HUE059827T2 (hu) 2023-01-28
RS63703B1 (sr) 2022-11-30
JP2021505535A (ja) 2021-02-18
IL274711B1 (en) 2024-06-01
US20190290725A1 (en) 2019-09-26
ZA202002821B (en) 2021-08-25
EP4279135A3 (en) 2024-02-21
IL312323A (en) 2024-06-01
SG11202004268PA (en) 2020-06-29
MX2020005166A (es) 2020-09-03
KR20200093621A (ko) 2020-08-05
EP4122486A1 (en) 2023-01-25
CA3083611A1 (en) 2019-06-06
IL274711B2 (en) 2024-10-01
US20210205410A1 (en) 2021-07-08
EP4279135A2 (en) 2023-11-22
KR20240074890A (ko) 2024-05-28

Similar Documents

Publication Publication Date Title
IL274711A (en) Use of a vegf antagonist to treat angiogenic eye disorders
IL260167A (en) For the treatment of vegf disorders - use of an agonist for angiogenic eyes
EP3525735A4 (en) THERAPEUTIC ULTRASOUND FOR EYE DISEASES
GB201610695D0 (en) Eye massaging device
EP3139914C0 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS
SG11201506309SA (en) Eye massager
IL267229A (en) Methods of treating ocular disorders
HUE066769T2 (hu) Neurodegeneratív szembetegség kezelése pridopidinnal
EP3419666A4 (en) ALPHA-1-adrenergic receptor agonist THERAPY
SG11201608257RA (en) A device for a medical treatment of a sclera
HK1205924A1 (en) Eye massager
ZA201702403B (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
HK1222535A1 (zh) 下肢用按摩器
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
IL270362B (en) Glaucoma treatment
GB201607388D0 (en) Treatment of impulsivity-related disorders
HUE052158T2 (hu) Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
PL3047824T3 (pl) Urządzenie do laserowej terapii ludzkiego oka
HK1220144A1 (zh) -叔丁基-苄基 -氯- -氯- -乙基-苯基 -乙基 -氟- -三氟甲基-苯甲酰胺用於治療眼疾病的用途
IL234962A0 (en) Use of substances to treat fat-related diseases
GB201604359D0 (en) Treatment of tissue disorders
SG11201709221QA (en) Lower limb exercise assisting device
GB201602640D0 (en) Treatment of fibrotic disorders
GB201602641D0 (en) Treatment of fibrotic disorders